CATETERE URETERALE DI TIPO FLEXI-TIP

Informazioni principali

  • Nome commerciale:
  • CATETERE URETERALE DI TIPO FLEXI-TIP
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • CATETERE URETERALE DI TIPO FLEXI-TIP
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • SONDE URETERALI - ALTRE

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 01-01-2010
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

17-12-2018

 Occupational health: aiming to take better account of multiple exposure

Occupational health: aiming to take better account of multiple exposure

Workers can potentially be exposed to numerous health risk factors through their occupations. The question of multiple exposure is a major challenge for all those active in the field of occupational health, safety and prevention. As part of the 2016-2020 National Occupational Health Plan, a review of the measures taken by the main players to address the question of multiple exposure in France and abroad is being published today. This work has helped determine the state of knowledge and the issues surroun...

France - Agence Nationale du Médicament Vétérinaire

17-12-2018

Occupational health: aiming to take better account of multiple exposure

Occupational health: aiming to take better account of multiple exposure

France - Agence Nationale du Médicament Vétérinaire

7-12-2018

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

FDA - U.S. Food and Drug Administration

29-11-2018

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab).

FDA - U.S. Food and Drug Administration

27-11-2018

Achdut Recalls Multiple Brands of "Tahini" Because It May Be Contaminated with Salmonella

Achdut Recalls Multiple Brands of "Tahini" Because It May Be Contaminated with Salmonella

Achdut LTD. of Ariel, Israel, is recalling its Tahini products of all packages and sizes produced on the following dates: April 7th to May 21st 2018, because it may be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.

FDA - U.S. Food and Drug Administration

20-11-2018

FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)

FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)

FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)

FDA - U.S. Food and Drug Administration

20-11-2018

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started or while it was being taken. This MS worsening is rare but can result in permanent disability.

FDA - U.S. Food and Drug Administration

13-11-2018

Registration Reminder: FDA Center for Veterinary Medicine Public Webinar about Genome Editing in Animals on Dec. 3

Registration Reminder: FDA Center for Veterinary Medicine Public Webinar about Genome Editing in Animals on Dec. 3

On Dec. 3, 2018, FDA’s Center for Veterinary Medicine (CVM) will hold a public webinar about genome editing in animals, focusing mainly on current scientific evidence, promising uses of this technology in animals, the potential risks & CVM’s flexible, risk-based approach to regulation.

FDA - U.S. Food and Drug Administration

12-11-2018

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins (Medische Zorg), Ambulancezorg Nederland (AZN) en Zorgverzekeraars Nederland (ZN) presenteerden vandaag het actieplan ambulancezorg. Het actieplan bevat verbeteringen waarmee ambulancezorg efficiënter kan worden ingezet en waarmee de opleiding en inzet van personeel in de regio’s gestroomlijnd wordt. Ook is er aandacht voor het aantrekkelijker maken van de vakopleiding. Door meer flexibiliteit in de bekostiging van ambulancezorg wordt het makkelijker om maatwerk te leveren in de reg...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

16-10-2018

Abond Group Inc. recalls Tubeez Baby Bath Support

Abond Group Inc. recalls Tubeez Baby Bath Support

The bath support’s suction cups may not adhere to the bath surface, making it unstable and cause it to possibly tip over while in use. In addition, an infant can slip underneath the front support bar and become lodged under water posing a drowning hazard.

Health Canada

11-10-2018

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Published on: Wed, 10 Oct 2018 00:00:00 +0200 This report provides a review of existing models for predicting the spatial distribution and abundance of wild boar at various scales (global, continental, national and regional) in order to inform the development of a new model to produce estimates of wild boar abundance at European level. The review identifies and discusses a range of models based on a wide variety of data types, corresponding to those targeted by the data collection model set by ENETwild,...

Europe - EFSA - European Food Safety Authority Publications

9-10-2018

Notice of call for expressions of interest - Multiplex serologie

Notice of call for expressions of interest - Multiplex serologie

France - Agence Nationale du Médicament Vétérinaire

28-9-2018

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA - U.S. Food and Drug Administration

18-9-2018

Les Distributions Orca Lite Inc. recalls FLEXI LIGHT multi-purpose utility lighters

Les Distributions Orca Lite Inc. recalls FLEXI LIGHT multi-purpose utility lighters

Health Canada's sampling and evaluation program has determined that these lighters do not meet the Lighters Regulations in Canada and may pose a fire or burn hazard. Specifically, the child-resistant mechanism may not work properly.

Health Canada

6-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on an updated approach for including added sugar information on the Nutrition Facts labels of pure maple syrup and honey

Statement from FDA Commissioner Scott Gottlieb, M.D., on an updated approach for including added sugar information on the Nutrition Facts labels of pure maple syrup and honey

Proposed rule revises front of package calorie labeling requirements to provide more flexibility to industry

FDA - U.S. Food and Drug Administration

1-9-2018

Multiple “Dr. King’s” homeopathic and “Natural Pet” veterinary products recalled due to potential microbial contamination

Multiple “Dr. King’s” homeopathic and “Natural Pet” veterinary products recalled due to potential microbial contamination

Health Canada is advising consumers and pet owners not to use homeopathic and veterinary products made by King Bio Inc. and labeled as "Dr. King's," "Dr King's Natural Pet" or "Natural Pet." These products may pose a health risk to people and pets, especially children, pregnant women and those with compromised immune systems, because of potential microbial contamination. According to the United States Food and Drug Administration, high levels of microbial contamination were identified at the manufacturin...

Health Canada

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

7-8-2018

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Mojave Foods Corporation is initiating a voluntary recall of four sizes of El Guapo Jamaica Hibiscus Flower packages in flexible packaging due to an unlabeled peanut allergen

FDA - U.S. Food and Drug Administration

2-8-2018

Orphan designation:  Pomalidomide,  for the: Treatment of multiple myeloma

Orphan designation: Pomalidomide, for the: Treatment of multiple myeloma

Europe - EMA - European Medicines Agency

18-7-2018

Orphan designation:  Thalidomide,  for the: Treatment of multiple myeloma

Orphan designation: Thalidomide, for the: Treatment of multiple myeloma

Europe - EMA - European Medicines Agency

26-6-2018

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Health Canada's sampling and evaluation program has determined that these lighters do not meet the Lighters Regulations in Canada and may pose a fire or burn hazard. Specifically the lighters:

Health Canada

22-6-2018

Kabinet wil mensen kansen geven op werk, ontwikkeling en invloed

Kabinet wil mensen kansen geven op werk, ontwikkeling en invloed

De samenleving verandert door globalisering, technologische vooruitgang en flexibilisering. Sommige mensen varen daar wel bij, anderen raken achterop. Het kabinet vindt het belangrijk dat iedereen in de samenleving kan blijven meedoen. Daarom moeten mensen meer kansen krijgen: om zich te ontwikkelen, op de arbeidsmarkt, en om hun eigen omgeving te beïnvloeden. Dit schrijft minister Koolmees van Sociale Zaken en Werkgelegenheid aan de Tweede Kamer, mede namens de ministers van Onderwijs, Cultuur en Wetens...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

29-5-2018

Orphan designation:  Panobinostat,  for the: Treatment of multiple myeloma

Orphan designation: Panobinostat, for the: Treatment of multiple myeloma

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Venetoclax,  for the: Treatment of multiple myeloma

Orphan designation: Venetoclax, for the: Treatment of multiple myeloma

Europe - EMA - European Medicines Agency

29-5-2018

Expanded Recall: Stroller Boutique recalls Anex Sport stroller

Expanded Recall: Stroller Boutique recalls Anex Sport stroller

Health Canada’s sampling and evaluation program has determined these strollers do not meet the Carriages and Strollers Regulations in Canada. Specifically, the strollers contain barium in excess of allowable limits. Additionally, these strollers do not meet Health Canada's stability requirements. These strollers may tip-over while in use, posing a fall hazard.

Health Canada

11-5-2018

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

FDA approves Gilenya (fingolimod) to treat multiple sclerosis MS in children age 10 and older. This is the first FDA approval of a drug to treat MS in pediatric patients

FDA - U.S. Food and Drug Administration

27-6-2011

Danish Pharmacovigilance Update, 16 June 2011

Danish Pharmacovigilance Update, 16 June 2011

Among the articles in this issue of Danish Pharmacovigilance Update, you can read about the removal of contraindication for Velcade® (bortezomib) used for the treatment of multiple myeloma.

Danish Medicines Agency

10-1-2019


Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

25-9-2018

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices:  http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: https://go.usa.gov/xPjCj  pic.twitter.com/yVSNlc5Qb0

FDA - U.S. Food and Drug Administration

6-8-2018

Scientific guideline:  Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

Scientific guideline: Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

The guideline aims to address the use of undetectable minimal residual disease (MRD) as an intermediate efficacy endpoint in controlled randomised clinical studies in patients with multiple myeloma (MM), adequately designed to demonstrate efficacy by relevant hard endpoints. MRD as an endpoint in this context would allow earlier approval of new drugs pending final confirmatory data.

Europe - EMA - European Medicines Agency

5-7-2018

Aggiornamento modelli delle variazioni tipo I rientranti nell'applicazione della Determina AIFA 25/08/2011 (05/07/2018)

Aggiornamento modelli delle variazioni tipo I rientranti nell'applicazione della Determina AIFA 25/08/2011 (05/07/2018)

Si porta all’attenzione di tutte le Aziende Farmaceutiche che, relativamente a medicinali autorizzati con procedura Nazionale o Mutuo Riconoscimento/Decentrata, l’Agenzia Italiana del Farmaco aggiorna i modelli per la pubblicazione in Gazzetta Ufficiale della Repubblica italiana delle variazioni rientranti nell’applicazione della Determina AIFA 25/08/2011 relativa alla procedura del silenzio/assenso.

Italia - AIFA - Agenzia Italiana del Farmaco

12-6-2018

Tipologie di procedimenti - aggiornamento sezione

Tipologie di procedimenti - aggiornamento sezione

L'Agenzia Italiana del Farmaco, ai sensi del d.lgs. 33/2013, rende disponibili aggiornamenti della sezione "Tipologie di procedimenti".

Italia - AIFA - Agenzia Italiana del Farmaco

14-5-2018

Are you wondering what you should discuss with your doctor at your annual checkup?

Pro tip: Use our checklist as a starting point.  https://go.usa.gov/xQg4q  #NWHWpic.twitter.com/A44He0N4sf

Are you wondering what you should discuss with your doctor at your annual checkup? Pro tip: Use our checklist as a starting point. https://go.usa.gov/xQg4q  #NWHWpic.twitter.com/A44He0N4sf

Are you wondering what you should discuss with your doctor at your annual checkup? Pro tip: Use our checklist as a starting point. https://go.usa.gov/xQg4q  #NWHW pic.twitter.com/A44He0N4sf

FDA - U.S. Food and Drug Administration